Post by 20/15 Visioneers

Most antibody fragments fail not because they can’t bind, but because they become unstable and can't stay together.   scFv antibody fragments are powerful therapeutic and diagnostic tools, but instability can limit shelf life, manufacturability, and development potential.   Our Client, STABLEBODY TECHNOLOGIES, LLC, is engineering stability at the sequence level through our computational platform, AffiBioXP.   AffiBioXP uses co-evolutionary patterns from natural antibody families to identify sequence changes that may improve thermal stability while preserving binding.   What AffiBioXP can support: • Thermostability enhancement • Capacity for development profiling • Solubility and aggregation resistance • Multi-parameter sequence optimization • Faster computational evaluation of mutation combinations   We also have a library of 20+ in silico–designed scFvs across oncology, infectious disease, anti-narcotic, and other challenging target areas.   Beyond antibodies, AffiBioXP has expanded into enzyme expression risk assessment, helping identify sequence-based expression liabilities across multiple organism systems.   All predictions are computational and intended for experimental validation, giving partners a sharper starting hypothesis for protein-engineering programs.   If stability is on your critical path, let’s talk [email protected]   #ProteinEngineering #AntibodyDesign #Biotech #ComputationalBiology #scFv #DrugDevelopment #Enzymes